최신 에피소드 🔗
Prof Gribben (Queen Mary University London, London, UK) and Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) review the data and opinions arising from ASH 2014 about the treatment of chronic lymphocytic leukaemia (CLL) for ecancertv.
The experts offer a comprehensive analysis of the curr…
이전 에피소드 🔗
Prof Keith Stewart of the Mayo Clinic, Scottsdale, USA talks to ecancertv at ASH 2014 about the phase III ASPIRE study looking at the use of carfilzomib in multiple myeloma.
“By adding carfilzomib to the gold standard in multiple myeloma therapy, we are observing an unprecedented duration of remis…
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA talks to ecancertv at ASH 2014 about the use of T cell therapy for children with aggressive leukaemia.
Prof Marivi Mateos of the University Hospital of Salamanca, Salamanca, Spain speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma.
Prof Burnett (Head of Haematology Department of Medical Genetics, Cardiff, Wales) and Prof Amadori (Tor Vergata University Hospital, Rome, Italy) review the data and opinions arising from ASH 2014 about the treatment of acute myeloid leukaemia (AML) for ecancertv.
They debate the use of intensifie…
Dr Craig Moskowitz of the Memorial Sloan Kettering Cancer Center, New York, USA talks to ecancertv at ASH 2014 about the findings of a phase III trial which compared brentuximab vedotin (BV), an antibody targeting the CD30 protein on Hodgkin lymphoma cells, with placebo in 327 patients at risk of p…
Dr Thomas Martin, MD, of the University of California, San Francisco, USA talks to ecancertv at ASH 2014 about his work looking at the use of SAR, an anti-CD38 antibody, in the treatment of aggressive multiple myeloma.
Dr Joe Alvarnas of the City of Hope National Medical Center, Los Angeles, USA talks to ecancertv at ASH 2014 about his work looking at stem cell transplants in HIV-associated lymphoma. "They're rather extraordinary results," he says.
Prof Amrita Krishnan of the City of Hope National Medical Center, Los Angeles, USA "Ultimately, if you really want to 'win the game,' you have to cure the HIV and cure the lymphoma," Prof Krishnan tells ecancertv at ASH 2014, describing her work on modifying haematopoietic progenitor cells with gen…
Dr Catherine Bollard of the George Washington University, Washington, USA discusses key abstracts showcased at ASH 2014 with ecancertv. Here, she talks about Dr Stephan Grupp's work with T cell therapy for children with aggressive leukaemia, and his remarkable results. What's the next step for clin…
면책 조항: 이 페이지에 포함된 팟캐스트와 작품은 ecancertv에서 가져온 것입니다. 이 팟캐스트는 소유자의 재산이며 Listen Notes, Inc.와 제휴하거나 보증하지 않습니다.
팟캐스트 검색 엔진
당사 웹사이트를 사용하여3,822,241팟캐스트 및195,487,210에피소드를 사람, 장소 또는 주제별로 검색할 수 있습니다.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
이 팟캐스트 요청하기
Why to claim podcasts?
If you are a podcaster, the best way to manage your podcasts on Listen Notes is by claiming your Listen Notes
podcast pages.
It is a great, free way to engage the podcast community and increase the visibility of your podcasts.
After claiming your Listen Notes podcast pages, you will be able to:
✓
Manually refresh the RSS feed to sync up
✓
Get a verified badge (
✓
) alongside with your podcast name on Listen Notes
✓
Post 분류 광고 for sponsorship,
guests, co-hosts,
cross-promotion...
✓
Respond to listener comments on Listen Notes
✓
Use speech-to-text techniques to transcribe your show and
edit transcripts
✓
Improve the presence of your podcasts, e.g., self-service
팟캐스터 인터뷰...
✓
If you share your Listen Notes page and at-mention @ListenNotes
on X (formerly Twitter),
공식 X(구 Twitter) 계정 will retweet to promote
your show to our followers.
Coming soon:
◯ Self-service promotion on Listen Notes
◯ Track your podcast stats on Listen
Notes, e.g., listens, page
views...
◯ Manage episodes
